Michael Wang, MD

Articles

Dr. Wang on the Significance of p53 Mutations in MCL

September 16th 2021

Michael Wang, MD, discusses the significance of p53 mutations in mantle cell lymphoma.

Dr. Wang on the Final Results of the ACE-LY-004 Trial in MCL

September 1st 2021

Michael Wang, MD, discusses the use of acalabrutinib in the phase 2 ACE-LY-004 trial in mantle cell lymphoma.

Dr. Wang on Future Research With CAR T-Cell Therapy in MCL

August 5th 2020

Michael Wang, MD, discusses the importance of additional CAR T-cell therapy research in mantle cell lymphoma.

Dr. Wang on the Safety Profile of Brexucabtagene Autoleucel in Relapsed/Refractory MCL

August 3rd 2020

Michael Wang, MD, discusses the safety profile of ​the CAR T-cell therapy brexucabtagene autoleucel in ​relapsed/refractory mantle cell lymphoma.

Dr. Wang on the FDA Approval of Brexucabtagene Autoleucel in MCL

July 24th 2020

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the FDA approval of brexucabtagene autoleucel (Tecartus; formerly KTE-X19) in mantle cell lymphoma (MCL).

Dr. Wang on the Efficacy of KTE-X19 in Low- and High-Risk R/R MCL

June 26th 2020

Michael Wang, MD, discusses the efficacy of KTE-X19 in low- and high-risk patients with relapsed/refractory mantle cell lymphoma as part of the phase 2 ZUMA-2 trial.

Dr. Wang on Comparative Analysis of KTE-X19 in Higher- Versus Lower-Risk R/R MCL

June 22nd 2020

Michael Wang, MD, discusses the objectives of a comparative analysis of the phase 2 ZUMA-2 trial with KTE-X19 in patients with mantle cell lymphoma.

Dr. Wang on the Safety and Efficacy of KTE-X19 in R/R MCL

June 20th 2020

Michael Wang, MD, discusses the safety and efficacy of KTE-X19 in relapsed/refractory mantle cell lymphoma.

Dr. Wang on the Impact of KTE-X19 on Outcomes in Higher- Versus Lower-Risk MCL

June 10th 2020

Michael Wang, MD, discusses the safety and effectiveness of the autologous anti-CD19 CAR T-cell therapy KTE-X19 in patients with higher- versus lower-risk mantle cell lymphoma.

Dr. Wang on Correlative Data From the ZUMA-2 Trial in MCL

June 2nd 2020

Michael Wang, MD, discusses correlative data from the phase 2 ZUMA-2 trial in mantle cell lymphoma (MCL).

Dr. Wang on Research Trends in MCL

May 16th 2020

Michael Wang, MD, discusses research trends in mantle cell lymphoma (MCL).

Dr. Wang on the Evolution of Treatment in MCL

May 14th 2020

Michael Wang, MD, discusses the evolution of treatment in mantle cell lymphoma.

Dr. Wang on the Evolution of Treatment in MCL

May 13th 2020

Michael Wang, MD, discusses the evolution of treatment in mantle cell lymphoma.

Dr. Wang on the Utility of CAR T-Cell Therapy in Relapsed/Refractory MCL

May 11th 2020

Michael Wang, MD, discusses the utility of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.

Dr. Wang on the Results of the ZUMA-2 Trial in Relapsed/Refractory MCL

May 8th 2020

Michael Wang, MD, discusses the results of the phase 2 ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

Dr. Wang on Unique Properties of KTE-X19 in Relapsed/Refractory MCL

May 5th 2020

Michael Wang, MD, discusses unique properties of the investigational CAR T-cell therapy KTE-X19 in relapsed/refractory mantle cell lymphoma.

Dr. Wang on Ongoing Research in MCL

April 7th 2020

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses ongoing research in mantle cell lymphoma (MCL).

Dr. Wang on the Safety Profile of KTE-X19 in MCL

March 3rd 2020

Michael Wang, MD, discusses the safety profile of the CAR T-cell therapy KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, according to results from the phase II ZUMA-2 trial.

Dr. Wang on the ZUMA-2 Trial in Relapsed/Refractory MCL

January 21st 2020

Michael Wang, MD, discusses the results of the phase II ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

Dr. Wang on Precision Medicine in MCL

January 17th 2020

Michael Wang, MD, discusses the move towards precision medicine in mantle cell lymphoma.